RUNX1 and kidney cancer: The lethality phenotype following CBFB loss is consistent both with observations made upon depletion of RUNX1 and RUNX2 in human kidney cancer lines68, and with CBF-β sitting among the top hits of a computational screening platform to identify synthetic lethal interactions of cancers24.